Physician profile
Nathaniel Pascual
NPI 1518020619
$1,842.44
in general payments reported to CMS, 2019-2025
15 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.29 · 2020: $183 · 2022: $827 · 2023: $304 · 2024: $279 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.52 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $855.99 | 2022-2023 | Inspire |
| Harmony Biosciences LLC | $214.04 | 2023-2024 | Wakix |
| Astrazeneca Pharmaceuticals LP | $157.32 | 2022-2025 | Fasenra, Breztri, Tezspire |
| Genentech USA, INC. | $155.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $104.82 | 2020-2025 | Trelegy Ellipta, Nucala |
| Avadel Cns Pharmaceuticals, LLC | $76.11 | 2025 | Lumryz |
| Grifols USA, LLC | $44.90 | 2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $42.80 | 2022-2025 | Dupixent |
| Philips North America LLC | $39.86 | 2023-2024 | (Ak6) Vest Therapy |
| Genzyme Corporation | $30.37 | 2022-2023 | |
| Allergan, INC. | $27.80 | 2020 | |
| Jazz Pharmaceuticals INC. | $26.04 | 2025 | |
| Electromed, INC. | $23.11 | 2024 | Smartvest |
| Abbvie INC. | $22.91 | 2024 | |
| Pfizer INC. | $21.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Pascual listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.